Halozyme Historical Income Statement

HALO Stock  USD 48.20  0.27  0.56%   
Historical analysis of Halozyme Therapeutics income statement accounts such as Selling General Administrative of 156.6 M or Selling And Marketing Expenses of 588 can show how well Halozyme Therapeutics performed in making a profits. Evaluating Halozyme Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Halozyme Therapeutics's future profits or losses.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Halozyme Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Halozyme Therapeutics is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.

About Halozyme Income Statement Analysis

Halozyme Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Halozyme Therapeutics shareholders. The income statement also shows Halozyme investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Halozyme Therapeutics Income Statement Chart

At this time, Halozyme Therapeutics' Other Operating Expenses is very stable compared to the past year. As of the 1st of December 2024, Operating Income is likely to grow to about 354.5 M, though Non Operating Income Net Other is likely to grow to (1.4 M).

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Total Revenue

Total revenue comprises all receipts Halozyme Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Halozyme Therapeutics minus its cost of goods sold. It is profit before Halozyme Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Operating Income

Operating Income is the amount of profit realized from Halozyme Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Halozyme Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most accounts from Halozyme Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Halozyme Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.At this time, Halozyme Therapeutics' Other Operating Expenses is very stable compared to the past year. As of the 1st of December 2024, Operating Income is likely to grow to about 354.5 M, though Non Operating Income Net Other is likely to grow to (1.4 M).
 2021 2022 2023 2024 (projected)
Gross Profit361.9M520.8M636.9M668.7M
Total Revenue443.3M660.1M829.3M870.7M

Halozyme Therapeutics income statement Correlations

0.460.920.020.920.90.90.80.820.870.950.760.160.30.650.6-0.110.65-0.12-0.260.6-0.041.0
0.460.64-0.280.620.630.690.460.460.470.540.720.380.090.340.320.460.350.240.50.31-0.060.44
0.920.64-0.20.940.930.980.770.780.820.940.890.270.130.620.520.120.63-0.06-0.140.520.140.91
0.02-0.28-0.2-0.12-0.13-0.250.020.020.02-0.07-0.360.090.140.010.08-0.48-0.02-0.02-0.150.09-0.150.04
0.920.620.94-0.121.00.910.930.940.960.980.760.250.010.840.34-0.080.84-0.3-0.150.340.190.91
0.90.630.93-0.131.00.90.930.940.960.970.760.240.00.840.32-0.070.85-0.3-0.120.320.190.9
0.90.690.98-0.250.910.90.70.720.760.920.950.280.260.550.530.280.56-0.030.010.520.090.89
0.80.460.770.020.930.930.71.00.990.890.470.18-0.210.960.12-0.380.96-0.5-0.260.120.250.8
0.820.460.780.020.940.940.721.01.00.910.490.18-0.170.960.15-0.370.96-0.48-0.260.150.230.82
0.870.470.820.020.960.960.760.991.00.940.550.18-0.10.930.22-0.340.93-0.44-0.270.230.20.87
0.950.540.94-0.070.980.970.920.890.910.940.750.250.060.790.4-0.120.79-0.28-0.230.40.180.95
0.760.720.89-0.360.760.760.950.470.490.550.750.280.370.310.560.540.330.170.190.560.020.75
0.160.380.270.090.250.240.280.180.180.180.250.28-0.060.160.030.160.16-0.020.110.010.130.16
0.30.090.130.140.010.00.26-0.21-0.17-0.10.060.37-0.06-0.360.660.41-0.360.530.210.66-0.620.3
0.650.340.620.010.840.840.550.960.960.930.790.310.16-0.36-0.14-0.451.0-0.67-0.28-0.140.420.65
0.60.320.520.080.340.320.530.120.150.220.40.560.030.66-0.140.18-0.140.64-0.041.0-0.650.61
-0.110.460.12-0.48-0.08-0.070.28-0.38-0.37-0.34-0.120.540.160.41-0.450.18-0.430.480.690.17-0.09-0.12
0.650.350.63-0.020.840.850.560.960.960.930.790.330.16-0.361.0-0.14-0.43-0.67-0.28-0.140.420.65
-0.120.24-0.06-0.02-0.3-0.3-0.03-0.5-0.48-0.44-0.280.17-0.020.53-0.670.640.48-0.670.230.64-0.57-0.12
-0.260.5-0.14-0.15-0.15-0.120.01-0.26-0.26-0.27-0.230.190.110.21-0.28-0.040.69-0.280.23-0.04-0.28-0.27
0.60.310.520.090.340.320.520.120.150.230.40.560.010.66-0.141.00.17-0.140.64-0.04-0.650.61
-0.04-0.060.14-0.150.190.190.090.250.230.20.180.020.13-0.620.42-0.65-0.090.42-0.57-0.28-0.65-0.04
1.00.440.910.040.910.90.890.80.820.870.950.750.160.30.650.61-0.120.65-0.12-0.270.61-0.04
Click cells to compare fundamentals

Halozyme Therapeutics Account Relationship Matchups

Halozyme Therapeutics income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization4.1M3.3M3.0M49.6M84.9M89.1M
Interest Expense11.6M20.4M7.5M16.9M18.8M19.7M
Selling General Administrative77.3M45.7M50.3M143.5M149.2M156.6M
Total Revenue196.0M267.6M443.3M660.1M829.3M870.7M
Gross Profit150.4M224.2M361.9M520.8M636.9M668.7M
Other Operating Expenses263.6M123.3M167.4M392.6M491.7M516.3M
Operating Income(67.6M)144.3M275.9M267.5M337.6M354.5M
Ebit(67.6M)144.3M275.9M265.9M367.1M385.4M
Ebitda(63.5M)147.5M278.9M315.5M451.9M474.5M
Cost Of Revenue45.5M43.4M81.4M139.3M192.4M202.0M
Total Operating Expenses218.1M80.0M86.0M253.3M299.3M314.3M
Income Before Tax(72.3M)129.3M248.5M248.9M348.3M365.7M
Total Other Income Expense Net(4.6M)(15.0M)(27.4M)(18.6M)10.8M11.3M
Net Income(72.2M)129.1M402.7M202.1M281.6M295.7M
Income Tax Expense(11K)217K(154.2M)46.8M66.7M70.1M
Research Development140.8M34.2M35.7M66.6M76.4M77.1M
Net Income From Continuing Ops(72.2M)129.1M402.7M202.1M281.6M295.7M
Non Operating Income Net Other7.0M5.4M(19.9M)(1.7M)(1.5M)(1.4M)
Net Income Applicable To Common Shares(72.2M)129.1M402.7M202.1M232.4M244.1M
Tax Provision(11K)217K(154.2M)46.8M66.7M70.1M
Net Interest Income(11.6M)(20.4M)(7.5M)(16.9M)(18.8M)(19.7M)
Reconciled Depreciation4.1M3.3M3.0M49.6M84.9M89.1M

Pair Trading with Halozyme Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Halozyme Stock

  0.64ELAN Elanco Animal HealthPairCorr

Moving against Halozyme Stock

  0.59ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.59EWTX Edgewise TherapeuticsPairCorr
  0.59BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.45GANX Gain TherapeuticsPairCorr
  0.43GILD Gilead SciencesPairCorr
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.721
Earnings Share
3.02
Revenue Per Share
7.431
Quarterly Revenue Growth
0.343
Return On Assets
0.1487
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.